1
|
Chen CJ, Huang YH, Hsu CW, Chen YC, Chang ML, Lin CY, Shen YH, Chien RN. Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up. BMC Gastroenterol 2023; 23:40. [PMID: 36782112 PMCID: PMC9926801 DOI: 10.1186/s12876-023-02665-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 02/03/2023] [Indexed: 02/15/2023] Open
Abstract
BACKGROUND AND AIM World Health Organization sets up an ambitious and attainable goal to eliminate hepatitis C (HCV) by 2030. The previous diagnosed HCV patients lost to follow-up were considered as an important target group for HCV elimination. We conducted a call back program to retrieve the lost to follow-up HCV patients and link them to care in our hospital. By analyzing and comparing our result with that from other studies, we wish to improve our retrieval strategy and provide our experience to the general communities. METHODS A list of the patients with a medical record showing seropositive for antibody to HCV (anti-HCV Ab) from 2004 to 2017 was retrieved by the department of intelligent technology of our hospital. Three dedicated staff members reviewed the patients' electronic medical records (EMRs) and recruited the patient lost follow-up to the call back program. The staff members contacted the qualified patients by telephone and inquired about their opinions for treating their chronic HCV infection. We also informed the patients about the retrieval strategy and why we contact them. As our National Health Insurance request, we gave all patient one informed consent for hepatitis C treatment. Informed consents have been obtained from all patients. Referrals to our gastroenterology unit (GU) were arranged for the patients who would like to continue their chronic HCV care in our hospital. RESULTS There were 31,275 anti-HCV positive patients. We included 11,934 patients (38.2%) into the call back system and contacted them by telephone. Based on the response to our call, we ascertained 1277 eligible cases (10.7%) for retrieval. The patients who were younger (< 55), lived in Taoyaun City or had tested positive for anti-HCV Ab at the department of internal medicine department had an increased rate of successful call back. There were 563 patients (44.1%) returning to our GU. Of them, 354 patients (62.9%) were positive for HCV viremia. 323 patients (91.2%) received the DAAs treatment. The SVR12 with Grazoprevir + elbasvir, Glecaprevir + pibrentasvir, Sofosbuvir + ledipasvir and Sofosbuvir + velpatasvir were 97.9%, 98.8%, 100% and 97.5%, respectively. CONCLUSIONS Call back system can expand our reach to those unaware or ignoring chronic HCV infection patients and link them to treatment.
Collapse
Affiliation(s)
- Cheng-Jen Chen
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC
| | - Yung-Hsin Huang
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC
| | - Chao-Wei Hsu
- Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC. .,Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC.
| | - Yi-Cheng Chen
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC ,grid.145695.a0000 0004 1798 0922Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC
| | - Ming-Ling Chang
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC ,grid.145695.a0000 0004 1798 0922Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC
| | - Chun-Yen Lin
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC ,grid.145695.a0000 0004 1798 0922Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC
| | - Yi-Hsien Shen
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC ,grid.145695.a0000 0004 1798 0922Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC
| | - Rong-Nan Chien
- grid.413801.f0000 0001 0711 0593Division of Hepato-Gastroenterology, Lin Kou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC ,grid.145695.a0000 0004 1798 0922Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC
| |
Collapse
|
2
|
Boeke CE, Adesigbin C, Adisa O, Agwuocha C, Akanmu MM, Anartati A, Aung KS, Azania A, Bello Nabe R, Budiman A, Chan Y, Chawla U, Fatchanuraliyah, Fernandes O, Grover GS, Naing TS, Ngo D, Ramers CB, Regan S, Sindhwani S, Tandy G, Tint K, Nguyen KV, Witschi M, McClure C. Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries. BMJ Open 2022; 12:e062745. [PMID: 36576192 PMCID: PMC9723848 DOI: 10.1136/bmjopen-2022-062745] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVES Given limited data on factors associated with hepatitis C virus (HCV) treatment discontinuation and failure in low- and middle-income countries, we aimed to describe patient populations treated for HCV in five countries and identify patient groups that may need additional support. DESIGN Retrospective cohort analysis using routinely collected data. SETTING Public sector HCV treatment programmes in India (Punjab), Indonesia, Myanmar, Nigeria (Nasarawa) and Vietnam. PARTICIPANTS 104 957 patients who initiated treatment in 2016-2022 (89% from Punjab). PRIMARY OUTCOMES Treatment completion and cure. RESULTS Patient characteristics and factors associated with outcomes varied across countries and facilities. Across all patients, median age was 40 years (IQR: 29-52), 30.6% were female, 7.0% reported a history of injecting drugs, 18.2% were cirrhotic and 4.9% were coinfected with HIV. 79.8% were prescribed sofosbuvir+daclastasvir. Of patients with adequate follow-up, 90.6% (89,551) completed treatment. 77.5% (69,426) of those who completed treatment also completed sustained virological testing at 12 weeks (SVR12), and of those, 92.6% (64 305) were cured. In multivariable-adjusted models, in most countries, significantly lower treatment completion was observed among patients on 24-week regimens (vs 12-week regimens) and those initiated in later years of the programme. In several countries, males, younger patients <20 years and certain groups of cirrhotic patients were less likely to complete treatment or be cured. In Punjab, treatment completion was also lower in those with a family history of HCV and people who inject drugs (PWID); in other countries, outcomes were comparable for PWID. CONCLUSION High proportions of patients completed treatment and were cured across patient groups and countries. SVR12 follow-up could be strengthened. Males, younger people and those with decompensated cirrhosis on longer regimens may require additional support to complete treatment and achieve cure. Adequate programme financing, minimal user fees and implementation of evidence-based policies will be critical to close gaps.
Collapse
Affiliation(s)
| | - Clement Adesigbin
- National AIDS/STIs Control Programme, Federal Ministry of Health, Abuja, FCT, Nigeria
| | | | | | | | | | - Khin Sanda Aung
- National Hepatitis Control Program, Department of Public Health, Ministry of Health, Naypyidaw, Myanmar
| | - Amy Azania
- Clinton Health Access Initiative, Boston, Massachusetts, USA
| | | | - Arief Budiman
- Clinton Health Access Initiative, Jakarta, Indonesia
| | - Yuhui Chan
- Clinton Health Access Initiative, Boston, Massachusetts, USA
| | | | - Fatchanuraliyah
- Directorate of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia
| | - Oriel Fernandes
- Clinton Health Access Initiative, Boston, Massachusetts, USA
| | - Gagandeep Singh Grover
- State Viral Hepatitis Management Unit, Department of Health and Family Welfare, Government of Punjab, Chandigarh, Punjab, India
| | | | - Dang Ngo
- Clinton Health Access Initiative, Hanoi, Viet Nam
| | | | - Sean Regan
- Clinton Health Access Initiative, Boston, Massachusetts, USA
| | | | - Gertrudis Tandy
- Directorate of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia
| | - Khin Tint
- Clinton Health Access Initiative, Yangon, Myanmar
| | | | | | - Craig McClure
- Clinton Health Access Initiative, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Assoumou SA, Tasillo A, Vellozzi C, Eftekhari Yazdi G, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. Clin Infect Dis 2021; 70:1388-1396. [PMID: 31095676 DOI: 10.1093/cid/ciz383] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 05/14/2019] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Hepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release. METHODS We used individual-based simulation modeling with healthcare and Department of Corrections (DOC) perspectives for CE and BI analyses, respectively. We simulated a US prison cohort at entry using published data and Washington State DOC individual-level data. We considered permutations of testing (risk factor based, routine at entry or at release, no testing), treatment (if liver fibrosis stage ≥F3, for all HCV infected or no treatment), and linkage to care (at release or no linkage). Outcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness ratios; DOC costs (2016 US dollars); and BI (healthcare cost/prison entrant) to generalize to other states. RESULTS Compared to "no testing, no treatment, and no linkage to care," the "test all, treat all, and linkage to care at release" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54% at a DOC annual additional cost of $1440 per prison entrant, and would be cost-effective. At current drug prices, targeted testing and liver fibrosis-based treatment provided worse outcomes at higher cost or worse outcomes at higher cost per QALY gained. In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at previous higher drug costs. CONCLUSIONS Although costly, widespread testing and treatment in prisons is considered to be of good value at current drug prices.
Collapse
Affiliation(s)
- Sabrina A Assoumou
- Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts.,Section of Infectious Disease, Department of Medicine, Boston University School of Medicine, Massachusetts
| | - Abriana Tasillo
- Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts
| | - Claudia Vellozzi
- Grady Health System, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Golnaz Eftekhari Yazdi
- Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts
| | - Jianing Wang
- Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts
| | - Shayla Nolen
- Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts
| | - Liesl Hagan
- Prevention Branch, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - William Thompson
- Prevention Branch, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Lara Strick
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.,Washington State Department of Corrections, Tumwater
| | | | - Benjamin P Linas
- Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts.,Section of Infectious Disease, Department of Medicine, Boston University School of Medicine, Massachusetts.,Department of Epidemiology, Boston University School of Public Health, Massachusetts
| |
Collapse
|
4
|
Simpson H, Manley P, Lawler J, Morey S, Buchanan E, Hewett M, Knowles J, Miller C, McCarron B, Valappil M, McPherson S. Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. J Public Health (Oxf) 2020; 41:700-706. [PMID: 30351415 DOI: 10.1093/pubmed/fdy190] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 09/21/2018] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND A large proportion of the 200 000 HCV-infected individuals in the UK are undiagnosed or lost to follow-up. Engaging known infected individuals in treatment is essential for elimination. METHODS Using PHE surveillance data and HCV treatment registers from North East of England (NE) treatment centres for 1997-2016, we estimated the number of HCV cases not linked to treatment and the proportion with active infection. We compared distances of treated and untreated cases to treatment services, and assessed the effect of expanding HCV treatment into existing drug and alcohol treatment centres in the NEE on treatment accessibility. RESULTS The odds of being treated was associated with distance to treatment services. Confirmatory results for ~50% were not reported to PHE NE. Overall, 3385 patients reported to PHE NE had no record of treatment; we estimated 1621 of these may have been lost to follow-up after confirmation of active infection. CONCLUSIONS Poor access to healthcare services may contribute to under-diagnosis or loss to follow-up. Expanding HCV treatment delivery into NEE drug and alcohol treatment centres would improve the accessibility of treatment services to people infected with/at risk of HCV. This may increase the proportion receiving treatment and support progress towards elimination.
Collapse
Affiliation(s)
- H Simpson
- London School of Hygiene and Tropical Medicine, London, UK
| | - P Manley
- Field Epidemiology Service Newcastle, National Infection Service, Public Health England, Newcastle upon Tyne, UK
| | - J Lawler
- Public Health England, North East Health Protection Team, Newcastle upon Tyne, UK
| | - S Morey
- Department of Health and Life Science, Northumbria University, Newcastle upon Tyne, UK
| | - E Buchanan
- Viral Hepatitis Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
| | - M Hewett
- Viral Hepatitis Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
| | - J Knowles
- Centre for Infection, James Cook University Hospital, Middlesbrough, UK
| | - C Miller
- Viral Hepatitis Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
| | - B McCarron
- Centre for Infection, James Cook University Hospital, Middlesbrough, UK
| | - M Valappil
- Viral Hepatitis Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Public Health Laboratory North East, PHE, Newcastle upon Tyne, UK
| | - S McPherson
- Viral Hepatitis Service, Newcastle upon Tyne Hospitals NHS Foundation Trust (Institute of Cellular Medicine, Newcastle University), Newcastle upon Tyne, UK
| |
Collapse
|
5
|
Kracht PAM, Arends JE, Hoepelman AIM, Vervoort SCJM. The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study. PLoS One 2020; 15:e0230756. [PMID: 32282805 PMCID: PMC7153871 DOI: 10.1371/journal.pone.0230756] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 03/07/2020] [Indexed: 02/06/2023] Open
Abstract
Background In the foreseeable future, patients with hepatitis C virus (HCV) with good healthcare access will all have been cured and the lost to follow-up (LFU) HCV-population will increasingly exist of hard-to-reach patients. Efforts to retrieve these individuals with HCV have been moderately successful so far. A deeper understanding of the reasons for loss to follow-up and the underlying processes is lacking. Aims To explore reasons for previous loss to follow-up in patients with HCV who have been brought back into care. Methods In 2017, fifteen patients with HCV who were evaluated at the University Medical Center Utrecht (UMCU) Infectious diseases outpatient clinic as part of the “REtrieval And cure of Chronic Hepatitis C” (REACH)-project were included in this study through convenience sampling. Face-to-face semi-structured in-depth interviews were conducted and a qualitative analysis based on the grounded theory was applied. Results A basic socio- psychological process named “maintaining the achieved balance” was uncovered in patients with HCV who were LFU. This “achieved balance” is the result of a transformative process following the initial HCV diagnosis. It is a steadfast stance in which participants keep HCV out of sight and in the margin of their lives in order to reestablish an optimal state of well-being. The balancing perspective is subsequently defended by repeated evasive behavioral patterns to avoid confrontation with the disease. Conclusion The balancing perspective gives insight into why individuals with HCV were not retained in care but also why they remained LFU thereafter. Physicians should realize that this mindset can be persistent and repeated efforts may be needed to finally trace and retrieve these patients.
Collapse
Affiliation(s)
- Patricia A. M. Kracht
- Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
- * E-mail:
| | - Joop E. Arends
- Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Andy I. M. Hoepelman
- Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | | |
Collapse
|
6
|
White L, Azzam A, Burrage L, Orme C, Kay B, Higgins S, Kaye S, Sloss A, Broom J, Weston N, Mitchell J, O’Beirne J. Facilitating treatment of HCV in primary care in regional Australia: closing the access gap. Frontline Gastroenterol 2019; 10:210-216. [PMID: 31288252 PMCID: PMC6583569 DOI: 10.1136/flgastro-2018-101049] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 09/14/2018] [Accepted: 09/29/2018] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Australia has unrestricted access to direct-acting antivirals (DAA) for hepatitis C virus (HCV) treatment. In order to increase access to treatment, primary care providers are able to prescribe DAA after fibrosis assessment and specialist consultation. Transient elastography (TE) is recommended prior to commencement of HCV treatment; however, TE is rarely available outside secondary care centres in Australia and therefore a requirement for TE could represent a barrier to access to HCV treatment in primary care. OBJECTIVES In order to bridge this access gap, we developed a community-based TE service across the Sunshine Coast and Wide Bay areas of Queensland. DESIGN Retrospective analysis of a prospectively recorded HCV treatment database. INTERVENTIONS A nurse-led service equipped with two mobile Fibroscan units assesses patients in eight locations across regional Queensland. Patients are referred into the service via primary care and undergo nurse-led TE at a location convenient to the patient. Patients are discussed at a weekly multidisciplinary team meeting and a treatment recommendation made to the referring GP. Treatment is initiated and monitored in primary care. Patients with cirrhosis are offered follow-up in secondary care. RESULTS 327 patients have undergone assessment and commenced treatment in primary care. Median age 48 years (IQR 38-56), 66% male. 57% genotype 1, 40% genotype 3; 82% treatment naïve; 10% had cirrhosis (liver stiffness >12.5 kPa). The majority were treated with sofosbuvir-based regimens. 26% treated with 8-week regimens. All patients had treatment prescribed and monitored in primary care. Telephone follow-up to confirm sustained virological response (SVR) was performed by clinic nurses. 147 patients remain on treatment. 180 patients have completed treatment. SVR data were not available for 19 patients (lost to follow-up). Intention-to-treat SVR rate was 85.5%. In patients with complete data SVR rate was 95.6%. CONCLUSION Community-based TE assessment facilitates access to HCV treatment in primary care with excellent SVR rates.
Collapse
Affiliation(s)
- Lauren White
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Ali Azzam
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Lauren Burrage
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Clare Orme
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Barbara Kay
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Sarah Higgins
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Simone Kaye
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Andrew Sloss
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | - Jennifer Broom
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia,University of Queensland, Brisbane, Queensland, Australia
| | - Nicola Weston
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
| | | | - James O’Beirne
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia,University of the Sunshine Coast, Sippy Downs, Queensland, Australia
| |
Collapse
|
7
|
Kosnik MB, Reif DM, Lobdell DT, Astell-Burt T, Feng X, Hader JD, Hoppin JA. Associations between access to healthcare, environmental quality, and end-stage renal disease survival time: Proportional-hazards models of over 1,000,000 people over 14 years. PLoS One 2019; 14:e0214094. [PMID: 30897121 PMCID: PMC6428249 DOI: 10.1371/journal.pone.0214094] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 03/06/2019] [Indexed: 01/31/2023] Open
Abstract
Prevalence of end-stage renal disease (ESRD) in the US increased by 74% from 2000 to 2013. To investigate the role of the broader environment on ESRD survival time, we evaluated average distance to the nearest hospital by county (as a surrogate for access to healthcare) and the Environmental Quality Index (EQI), an aggregate measure of ambient environmental quality composed of five domains (air, water, land, built, and sociodemographic), at the county level across the US. Associations between average hospital distance, EQI, and survival time for 1,092,281 people diagnosed with ESRD between 2000 and 2013 (age 18+, without changes in county residence) from the US Renal Data System were evaluated using proportional-hazards models adjusting for gender, race, age at first ESRD service date, BMI, alcohol and tobacco use, and rurality. The models compared the average distance to the nearest hospital (<10, 10-20, >20 miles) and overall EQI percentiles [0-5), [5-20), [20-40), [40-60), [60-80), [80-95), and [95-100], where lower percentiles are interpreted as better EQI. In the full, non-stratified model with both distance and EQI, there was increased survival for patients over 20 miles from a hospital compared to those under 10 miles from a hospital (hazard ratio = 1.14, 95% confidence interval = 1.12-1.15) and no consistent direction of association across EQI strata. In the full model stratified by average hospital distance, under 10 miles from a hospital had increased survival in the worst EQI strata (median survival 3.0 vs. 3.5 years for best vs. worst EQI, respectively), however for people over 20 miles from a hospital, median survival was higher in the best (4.2 years) vs worst (3.4 years) EQI. This association held across different rural/urban categories and age groups. These results demonstrate the importance of considering multiple factors when studying ESRD survival and future efforts should consider additional components of the broader environment.
Collapse
Affiliation(s)
- Marissa B. Kosnik
- Toxicology Program, Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina, United States of America
- Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, United States of America
| | - David M. Reif
- Toxicology Program, Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina, United States of America
- Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, United States of America
- Center for Human Health and the Environment, North Carolina State University, Raleigh, North Carolina, United States of America
| | - Danelle T. Lobdell
- National Health and Environmental Effects Research Lab, U.S. EPA, Chapel Hill, North Carolina, United States of America
| | - Thomas Astell-Burt
- Population Wellbeing and Environment Research Lab, School of Health and Society, Faculty of Social Sciences, University of Wollongong, Wollongong, New South Wales, Australia
- Menzies Centre for Health Policy, University of Sydney, Sydney, New South Wales, Australia
- School of Public Health, Peking Union Medical College and The Chinese Academy of Medical Sciences, Beijing, China
| | - Xiaoqi Feng
- Population Wellbeing and Environment Research Lab, School of Health and Society, Faculty of Social Sciences, University of Wollongong, Wollongong, New South Wales, Australia
- Menzies Centre for Health Policy, University of Sydney, Sydney, New South Wales, Australia
| | | | - Jane A. Hoppin
- Toxicology Program, Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina, United States of America
- Center for Human Health and the Environment, North Carolina State University, Raleigh, North Carolina, United States of America
| |
Collapse
|
8
|
Machado SM, Almeida CD, Pinho JRR, Malta FDM, Capuani L, Campos AF, Abreu FRM, Nastri ACDSS, Santana RAF, Sabino EC, Mendes-Correa MC. Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up. Rev Saude Publica 2017; 51:40. [PMID: 28489184 PMCID: PMC5396505 DOI: 10.1590/s1518-8787.2017051006468] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 03/07/2016] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVE To investigate the HCV cascade of care and to identify the factors associated with loss or absence to follow-up of patients identified as infected with hepatitis C through blood donation. METHODS Blood donors from 1994 to 2012, identified with positive anti- HCV by enzyme immunoassay and immunoblot tests were invited to participate in the study, through letters or phone calls. Patients who agreed to participate were interviewed and their blood samples were collected for further testing. The following variables were investigated: demographic data, data on comorbidities and history concerning monitoring of hepatitis C. Multiple regression analysis by Poisson regression model was used to investigate the factors associated with non-referral for consultation or loss of follow-up. RESULTS Of the 2,952 HCV-infected blood donors, 22.8% agreed to participate: 394 (58.2%) male, median age 48 years old and 364 (53.8%) Caucasian. Of the 676 participants, 39.7% did not receive proper follow-up or treatment after diagnosis: 45 patients referred not to be aware they were infected, 61 did not seek medical attention and 163 started a follow-up program, but were non-adherent. The main reasons for inadequate follow-up were not understanding the need for medical care (71%) and health care access difficulties (14%). The variables showing a significant association with inadequate follow-up after multiple regression analysis were male gender (PR = 1.40; 95%CI 1.15–1.71), age under or equal to 50 years (PR = 1.36; 95%CI 1.12–1.65) and non-Caucasians (PR = 1.53; 95%CI 1.27–1.84). CONCLUSIONS About 40.0% of patients did not receive appropriate follow-up. These data reinforce the need to establish strong links between primary care and reference centers and the need to improve access to specialists and treatments.
Collapse
Affiliation(s)
- Soraia Mafra Machado
- Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil
| | - Cesar de Almeida
- Fundação Pró-Sangue. Hemocentro de São Paulo. São Paulo, SP, Brasil
| | - João Renato Rebello Pinho
- Laboratório de Gastroenterologia e Hepatologia Tropical "João Alves de Queiroz e Castorina Bittencourt Alves" (LIM-07). Instituto de Medicina Tropical. Departamento de Gastroenterologia. Faculdade de Medicina. Universidade de São Paulo. São Paulo, Brasil.,Albert Einstein Medicina Diagnóstica. Hospital Israelita Albert Einstein. São Paulo, SP, Brasil
| | - Fernanda de Mello Malta
- Laboratório de Gastroenterologia e Hepatologia Tropical "João Alves de Queiroz e Castorina Bittencourt Alves" (LIM-07). Instituto de Medicina Tropical. Departamento de Gastroenterologia. Faculdade de Medicina. Universidade de São Paulo. São Paulo, Brasil
| | - Ligia Capuani
- Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil
| | - Aléia Faustina Campos
- Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil
| | - Fatima Regina Marques Abreu
- Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil
| | | | | | - Ester Cerdeira Sabino
- Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil
| | - Maria Cássia Mendes-Correa
- Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil.,Laboratório de Virologia (LIM-52). Instituto de Medicina Tropical de São Paulo. Departamento de Moléstias Infecciosas e Parasitárias. Faculdade de Medicina. Universidade de São Paulo, São Paulo, Brasil
| |
Collapse
|
9
|
Balkhy HH, El-Saed A, Sanai FM, Alqahtani M, Alonaizi M, Niazy N, Aljumah A. Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia. J Infect Public Health 2016; 10:379-387. [PMID: 27720641 DOI: 10.1016/j.jiph.2016.06.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2016] [Revised: 06/07/2016] [Accepted: 06/18/2016] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Non-adherence with recommended follow-up visits is a major barrier for completing treatment of viral hepatitis and is consequently associated with unfavorable outcomes of health services. OBJECTIVES To estimate the magnitude and identify perceived reasons and patient characteristics associated with loss to follow-up in a tertiary care setting. METHODS A two-step cross-sectional study design was used, including a chart review (2011) followed by phone survey (2012). Loss to follow-up was recorded among those who were diagnosed with hepatitis B (HBV) or C (HCV) during 2009-2010 but never returned for recommended/scheduled follow-up appointment(s). RESULTS A total of 328 patients (202 HBV and 126 HCV) were included in the current analysis. The average age was 49.6±17.9years, and 57% were males. Out of 328, 131 (40%) were not advised to do follow-up, and 98 (30%) were not doing follow-up. Perceived reasons for loss to follow-up were as follows: unaware that a follow-up appointment was scheduled (69%), never informed of need for follow-up by healthcare provider (15%), personal belief that follow-up was not necessary (9%), logistical reasons (3%) and other reasons (5%). Loss to follow-up was higher among those who had been diagnosed with HBV, referred by non-liver-related specialty, never advised to follow-up, unaware of their diagnosis, incorrectly identified their type of hepatitis, lacking hepatitis complications, having full medical coverage, pregnant, and those with low knowledge or negative attitude towards hepatitis. CONCLUSIONS Loss to follow-up is a significant problem among patients with hepatitis in a tertiary care center, with several patient and system failures being implicated.
Collapse
Affiliation(s)
- Hanan H Balkhy
- Department of Infection Prevention and Control, King Abdulaziz Medical City, Riyadh, Saudi Arabia; Gulf Cooperation Council (GCC) States and WHO Collaborating Center for Infection Prevention & Control, Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Department of Pediatrics, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
| | - Aiman El-Saed
- Department of Infection Prevention and Control, King Abdulaziz Medical City, Riyadh, Saudi Arabia; Gulf Cooperation Council (GCC) States and WHO Collaborating Center for Infection Prevention & Control, Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Community Medicine Department, Faculty of Medicine, Mansoura University, Egypt
| | - Faisal M Sanai
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Hepatology Division, King Abdulaziz Medical City, Riyadh, Saudi Arabia; Liver Disease Research Center, King Saud University, Riyadh, Saudi Arabia
| | - Mohammad Alqahtani
- Department of Infection Prevention and Control, King Abdulaziz Medical City, Riyadh, Saudi Arabia
| | - Mashael Alonaizi
- Department of Infection Prevention and Control, King Abdulaziz Medical City, Riyadh, Saudi Arabia
| | - Nermeen Niazy
- Community Medicine Department, Faculty of Medicine, Mansoura University, Egypt
| | - Abdulrahman Aljumah
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Hepatology Division, King Abdulaziz Medical City, Riyadh, Saudi Arabia
| |
Collapse
|
10
|
Poll R, Allmark P, Tod AM. Reasons for missed appointments with a hepatitis C outreach clinic: A qualitative study. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2016; 39:130-137. [PMID: 27939298 DOI: 10.1016/j.drugpo.2015.12.027] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 11/07/2015] [Accepted: 12/10/2015] [Indexed: 01/08/2023]
Abstract
BACKGROUND Non-attendance in drug service hepatitis C outreach clinics means clients miss the opportunity of being given lifestyle advice and referral to hospital for assessment and treatment. A similar problem is experienced in other services throughout the UK. A qualitative study was undertaken to investigate the problem. METHODS Clients with a history of not attending the outreach clinic were invited to participate during a routine drug clinic appointment. A contact details sheet with a preferred telephone number was completed by those agreeing to take part. Verbal consent was taken and a telephone interview took place. The participants were remunerated for taking part with a five pounds high street voucher. The 'framework method' was used to analyse the data with key themes identified. RESULTS Twenty-eight telephone interviews were undertaken from April to June 2012. All the clients gave 'prima-facie' reasons for non-attendance including 'not a priority' and 'forgot'. However, the study indicates these are insufficient to explain the various experiences and influences. Underlying reasons that impacted upon attendance were identified. These reasons relate to (i) client characteristics e.g. 'priority' to score drugs and the 'cost of travel' and (ii) clinic service e.g. 'difficult journey' to the clinic and timing of the 'appointment'. The reasons operated within a complex context where other factors had an impact including addiction, welfare policy, stigma and the nature of hepatitis C itself. CONCLUSION The study revealed that beneath apparently simple explanations for non-attendance, such as clients' chaotic lifestyle resulting in them forgetting or not being bothered to attend, there were far more complex and varied underlying reasons. This has important implications for drug policy including the need to better incorporate clients' perspectives. Policy that is based only on the simple, surface reasons is unlikely to be effective.
Collapse
Affiliation(s)
- Ray Poll
- Department of Infection and Tropical Medicine, The Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England, United Kingdom.
| | - Peter Allmark
- Centre for Health and Social Care Research, Montgomery House, 32 Collegiate Crescent, Collegiate Campus, Sheffield S10 2BP, England, United Kingdom
| | - Angela M Tod
- Faculty of Human and Medical Sciences, Room 5.319, Jean McFarlane Building, Oxford Road, Manchester M13 9PL, England, United Kingdom
| |
Collapse
|
11
|
Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med 2015; 30:950-7. [PMID: 25680353 PMCID: PMC4471023 DOI: 10.1007/s11606-015-3209-6] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Revised: 10/27/2014] [Accepted: 01/16/2015] [Indexed: 12/19/2022]
Abstract
BACKGROUND Many of the five million Americans chronically infected with hepatitis C (HCV) are unaware of their infection and are not in care. OBJECTIVE We implemented and evaluated HCV screening and linkage-to-care interventions in a community setting. DESIGN We developed a comprehensive, community-based HCV screening and linkage-to-care program in a medically underserved neighborhood with high rates of HCV infection in Philadelphia, Pennsylvania. We provided patient navigation services to enroll uninsured patients in insurance programs, facilitate referrals from primary care physicians and link patients to an HCV infectious disease specialist with intention to treat and cure. PATIENTS Philadelphia residents were recruited through street outreach. MAIN MEASURES We measured anti-HCV seroprevalence and diagnosis, linkage and retention in care outcomes for chronically infected patients. KEY RESULTS We screened 1,301 participants for HCV; anti-HCV seroprevalence was 3.9 % and 2.8% of all patients were chronically infected. Half of chronically infected patients were newly diagnosed; the remaining patients were aware of infection but not in care. We provided confirmatory RNA testing and results, assisted patients with attaining insurance and linked most chronically infected patients to a primary care provider. The biggest barrier to retaining patients in care was obtaining referrals for subspecialty providers; however, we obtained referrals for 64% of chronically infected participants and have retained most in subspecialty HCV care. Several have commenced treatment. CONCLUSIONS Non-clinical screening programs with patient navigator services are an effective means to diagnose, link, retain and re-engage patients in HCV care. Eliminating referral requirements for subspecialty care might further enhance retention in care for patients chronically infected with HCV.
Collapse
|
12
|
Whitehead NE, Hearn LE, Marsiske M, Kahn MR, Latimer WW. Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City. J Community Health 2014; 39:487-93. [PMID: 24173529 DOI: 10.1007/s10900-013-9782-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The present study sought to examine: (1) the prevalence and correlates of biologically confirmed Hepatitis C (HCV) and (2) the prevalence and correlates of prior HCV diagnosis and an unmet need for HCV treatment, among a community residing sample of drug users. The current study used a subset of HCV tested participants from the larger NEURO-HIV Epidemiologic Study from Baltimore, Maryland (M(age) = 34.81, SD = 9.25; 46% female). All participants were tested for HCV at baseline. Self-report was used to assess awareness of an HCV diagnosis and participation in treatment. Of the 782 participants tested for HCV, 19% reported having received an HCV diagnosis in the past while 48% tested positive for HCV. Only 6% reported having received treatment for any form of hepatitis. Of those who tested HCV positive, 63% reported never being diagnosed, and only 13% received any treatment for HCV. We found that only 35% of those who reported a prior HCV diagnosis received any treatment. The findings regarding lack of HCV awareness and diagnosis were considerable as expected. These deficits suggest that there are numerous gaps in patients' knowledge and beliefs regarding HCV that may interfere at multiple steps along the path from diagnosis to treatment. This study clearly demonstrates that a critical need exists to improve public knowledge of HCV risk factors, the need for testing, and the availability of effective treatment.
Collapse
Affiliation(s)
- Nicole Ennis Whitehead
- Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, 1225 Center Drive, Room 3146, Gainesville, FL, 32611, USA,
| | | | | | | | | |
Collapse
|
13
|
Cachay ER, Hill L, Wyles D, Colwell B, Ballard C, Torriani F, Mathews WC. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One 2014; 9:e102883. [PMID: 25036553 PMCID: PMC4103859 DOI: 10.1371/journal.pone.0102883] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Accepted: 06/24/2014] [Indexed: 12/12/2022] Open
Abstract
Background The aims were to investigate the hepatitis C (HCV) cascade of care among HIV-infected patients and to identify reasons for not referring for and not initiating HCV therapy after completion of HCV treatment staging. Design and Methods Retrospective cohort analysis of HIV-infected patients under care at the University of California, San Diego (UCSD). We identified patients screened for and diagnosed with active HCV infection. Logistic regression analyses were used to identify factors associated with lack of referral for HCV therapy. Electronic medical records were reviewed to ascertain reasons for not initiating HCV therapy. Results Between 2008 and 2012, 4725 HIV-infected patients received care at the UCSD Owen clinic. Most patients [4534 (96%)] were screened for HCV, 748 (16%) patients had reactive serum HCV antibodies but only 542 patients had active HCV infection. Lack of engagement in care was the most important predictor of non-referral for HCV therapy [odds ratio (OR): 5.08, 95% confidence interval 3.24–6.97, p<0.00001]. Other significant predictors included unstable housing (OR: 2.26), AIDS (OR: 1.83), having a detectable HIV viral load (OR: 1.98) and being non-white (OR: 1.67). The most common reason (40%) for not initiating or deferring HCV therapy was the presence of ongoing barriers to care. Conclusions Screening for HCV in HIV-infected patients linked to care is high but almost half of patients diagnosed with HCV are not referred for HCV therapy. Despite improvements in HCV therapy the benefits will not be realized unless effective measures for dealing with barriers to care are implemented.
Collapse
Affiliation(s)
- Edward R. Cachay
- Department of Medicine, Owen Clinic, University of California San Diego, San Diego, California, United States of America
- Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, California, United States of America
- * E-mail:
| | - Lucas Hill
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, California, United States of America
| | - David Wyles
- Department of Medicine, Owen Clinic, University of California San Diego, San Diego, California, United States of America
- Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, California, United States of America
| | - Bradford Colwell
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, California, United States of America
| | - Craig Ballard
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, California, United States of America
| | - Francesca Torriani
- Department of Medicine, Owen Clinic, University of California San Diego, San Diego, California, United States of America
- Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, California, United States of America
| | - William C. Mathews
- Department of Medicine, Owen Clinic, University of California San Diego, San Diego, California, United States of America
| |
Collapse
|
14
|
Stoewen DL, Coe JB, MacMartin C, Stone EA, Dewey CE. Factors influencing veterinarian referral to oncology specialists for treatment of dogs with lymphoma and osteosarcoma in Ontario, Canada. J Am Vet Med Assoc 2014; 243:1415-25. [PMID: 24171370 DOI: 10.2460/javma.243.10.1415] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To elucidate factors influencing practitioner decisions to refer dogs with cancer to veterinary oncology specialists. DESIGN Cross-sectional study. SAMPLE 2,724 Ontario primary care companion animal veterinarians. PROCEDURES Practitioners were invited to participate in a survey involving clinical scenarios of canine cancer patients, offered online and in paper format from October 2010 through January 2011. Analyses identified factors associated with the decision to refer patients to veterinary oncology specialists. RESULTS 1,071 (39.3%) veterinarians responded, of which 603 (56.3%) recommended referral for dogs with multicentric lymphoma and appendicular osteosarcoma. Most (893/1,059 [84.3%]) practiced within < 2 hours' drive of a specialty referral center, and most (981/1,047 [93.7%]) were completely confident in the oncology service. Few (230/1,056 [21.8%] to 349/1,056 [33.0%]) were experienced with use of chemotherapeutics, whereas more (627/1,051 [59.7%]) were experienced with amputation. Referral was associated with practitioner perception of patient health status (OR, 1.54; 95% confidence interval [CI], 1.15 to 2.07), the interaction between the client's bond with the dog and the client's financial status, practitioner experience with treating cancer (OR, 2.79; 95% CI, 1.63 to 4.77), how worthwhile practitioners considered treatment to be (OR, 1.66 to 3.09; 95% CI, 1.08 to 4.72), and confidence in the referral center (OR, 2.20; 95% CI, 1. 11 to 4.34). CONCLUSIONS AND CLINICAL RELEVANCE Several factors influenced practitioner decisions to refer dogs with lymphoma or osteosarcoma for specialty care. Understanding factors that influence these decisions may enable practitioners to appraise their referral decisions and ensure they act in the best interests of patients, clients, and the veterinary profession.
Collapse
Affiliation(s)
- Debbie L Stoewen
- Department of Population Medicine, University of Guelph, Guelph, ON N1G 2W1, Canada
| | | | | | | | | |
Collapse
|
15
|
Cachay ER, Hill L, Ballard C, Colwell B, Torriani F, Wyles D, Mathews WC. Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Res Ther 2013; 10:9. [PMID: 23537147 PMCID: PMC3620560 DOI: 10.1186/1742-6405-10-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2013] [Accepted: 03/21/2013] [Indexed: 02/06/2023] Open
Abstract
Background Access to Hepatitis C (HCV) care is low among HIV-infected individuals, highlighting the need for new models to deliver care for this population. Methods Retrospective cohort analysis that compared the number of HIV patients who initiated HCV therapy: hepatology (2005–2008) vs. HIV primary care model (2008–2011). Logistic-regression modeling was used to ascertain factors associated with HCV therapy initiation and achievement of sustained viral response (SVR). Results Of 196 and 163 patients that were enrolled in the HIV primary care and hepatology models, 48 and 26 were treated for HCV, respectively (p = 0.043). The HIV/HCV-patient referral rate did not differ during the two study periods (0.10 vs. 0.12/patient-yr, p = 0.18). In unadjusted analysis, predictors (p < 0.05) of HCV treatment initiation included referral to the HIV primary care model (OR: 1.7), a CD4+ count ≥400/mm3 (OR: 1.8) and alanine aminotranferase level ≥63U/L (OR: 1.9). Prior psychiatric medication use correlated negatively with HCV treatment initiation (OR: 0.6, p = 0.045). In adjusted analysis the strongest predictor of HCV treatment initiation was CD4+ count (≥400/mm3, OR: 2.1, p = 0.01). There was no significant difference in either clinic model (primary care vs. hepatology) in the rates of treatment discontinuation due to adverse events (29% vs. 16%), loss to follow-up (8 vs. 8%), or HCV SVR (44 vs. 35%). Conclusions Using a HIV primary care model increased the number of HIV patients who initiate HCV therapy with comparable outcomes to a hepatology model.
Collapse
|